Comparative Study in Treatment of Benign Childhood Epilepsy with Centrotemporal Spikes by Levetiracetam and Oxcarbazepine
Abstract: Objective: To clarify the therapeutic effect and the cognitive improvement of Levetiracetam (LEV) monotherapy on the first BECT (benign childhood epilepsy with centro-temporal spikes, BECT) compared with Oxcarbazepine (OXC) in an open and parallel study. Methods: 104 patients who were admitted in our hospital and conformed to the BECT diagnostic criteria were divided into two groups randomly: OXC therapy group (51 cases) and LEV therapy group (53 cases). The monthly average seizure times of the 3 months before the beginning of the study were taken as the baseline seizure level, while the seizures times were recorded after telephone follow-up or clinical return visits per 2 - 4 weeks. Evaluations on cognitive functions were conducted before the treatment and 3 months, 6 months and 12 months after the treatment (Wechslet preschool and primary scale of intelligence were applied to the patients at the age of 4 - 6, and Wechsler intelligence scale for children were applied to those at the age of 6 - 16). Results: 1) Comparison of curative effects: The curative effect difference between the LEV group and OXC group and the difference during the different period of each group were both not significant. 2) Comparison of cognitive function: There is no statistical difference between the two groups before and after treatment. Both the two groups showed an increasing trend of intelligence test scores after treatment. There was no statistical significance between scores before and after OXC treatment, while the scores difference of words and digit span before and after the treatment of LEV had statistical significance. Conclusions: The curative effect of LEV on the first BECT patients is similar to OXC without adverse influence on cognition.
文章引用: 单 玲 , 李洪华 , 杜 琳 , 王 冰 , 冯俊燕 , 贾飞勇 (2014) 左乙拉西坦和奥卡西平治疗伴中央颞区棘波儿童良性癫痫的对比研究。 国际神经精神科学杂志， 3， 28-34. doi: 10.12677/IJPN.2014.34005
 陈学谦, 金有豫 (2006) 新编药物学. 人民卫生出版社, 北京.
 Lynch, B.A., Lambeng, N., Nocka, K., et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America, 101, 9861-9866.
 Custer, K.L., Austin, N.S., Sullivan, J.M., et al. (2006) Synaptic vesicle protein 2 enhances release probability at quies- cent synapses. Journal of Neuroscience, 26, 1303-1313.
 Cereghino, J.J., Biton, V., Abou-Khalil, B., et al. (2000) Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial. Neurology, 55, 236-242.
 Glauser, T.A., Ayala, R., Elterman, R.D., et al. (2006) Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology, 66, 1654-1660.
 Opp, J., Tuxhorn, I., May, T., et al. (2005) Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure, 14, 476-484.
 Massa, R., de Saint-Martin, A., Careangiu, R., et al. (2001) EEG criteria predictive of complicated evolution in idiopathathic rolandic epilepsy. Neurology, 57, 1071-1079.
 Binnie, C.D. (2001) Cognitive performance, subtle seisure, and the EEG. Epilepsia, 42, S16-S18.
 Motamedi, G. and Meador, K. (2003) Epilepsy and cognition. Epilepsy & Behavior, 4, S25-S38.
 Sabers, A., Moller, A., Dam, M., Smed, A., Arlien-Soborg, P., Buchman, J., et al. (1995) Cognitive function and anticonvulsant therapy: Effect of monotherapy in epilepsy. Acta Neurologica Scandinavica, 92, 19-27.
 Aikiä,M., Kälviäinen, R., Sivenius, J., Halonen, T. and Riekkinen, P.J. (1992) Cognitive effects of ox-car-bazepine and phenytoin monotherapy in newly diagnosed epilepsy: One year follow-up. Epilepsy Research, 11, 199-203.
 Park, S.P., Hwang, Y.H., Kim, J.I., et al. (2002) Cognitive function in epileptic patients treated with oxcar-bazepine: Neuropsychologic test and event related potential. Journal of the Korean Neurological Association, 20, 27-33.
 Salinsky, M.C., Spencer, D.C., Oken, B.S., et al. (2004) Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers. Epilepsy Behavior, 5, 894-902.
 Donati, F., Gobbi, G., Campistol, J., Rapatz, G., Daehler, M., Sturm, Y., et al. (2006) Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology, 67, 679-682.
 Donati, F., Gobbi, G., Campistol, J., et al. (2007) The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure, 16, 670-679.
 Mecarelli, O., Vicenzini, E., Pulitano, P., et al. (2004) Clinical, cognitive, and neurophysiologic correlates of short- term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. Annals of Pharmacotherapy, 38, 1816-1822.
 Meador, K.J., Gevinsm A., Loringm D.W., et al. (2007) Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology, 69, 2076-2084.
 Piazzini, A., Chifari, R., Canevini, M.P., et al. (2006) Levetiracetam: An improvement of attention and of oral ﬂuency in patients with partial epilepsy. Epilepsy Research, 68, 181-188.
 Kim, J., Kondratyev, A. and Gale, K. (2007) Antiepileptic drug-induced neuronal cell death in the immature brain: Effects of carbamazepine, topiramate and levetiracetam as monotherapy vs. polytherapy. Journal of Pharmacology and Experimental Therapeutics, 323, 165-173.
 Lagae, L., Buyse, G. and Ceulemans, B. (2005) Clinical experience with levetiracetam in childhood epilepsy: An add- on and monotherapy trial. Seizure, 14, 66-71.